Want to see ARVN full AI Analyst Report?
Arvinas Holding Company (ARVN) AI Stock Analysis
Arvinas Holding Company
(NASDAQ:ARVN)
The score is driven primarily by mixed financial performance—strong balance-sheet flexibility and improved reported profitability, but significant ongoing operating/free-cash-flow burn. Earnings call commentary is a relative positive due to multiple upcoming clinical milestones and a runway into 2H 2028, but regulatory and early-dataset uncertainties remain. Technicals are neutral-to-weak with price below key longer-term averages, and valuation appears demanding with a high P/E and no dividend.
Arvinas Holding Company (ARVN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $485.20M
- Dividend Yield
- ―
- Average Volume (3M)
- 815.18K
- Price to Earnings (P/E)
- -47.3
- Beta (1Y)
- 1.34
- Revenue Growth
- -11.85%
- EPS Growth
- 81.44%
- Country
- US
- Employees
- 246
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Arvinas Holding Company Business Overview & Revenue Model
Company Description
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising...
How the Company Makes Money
As a clinical-stage biotechnology company, Arvinas has historically generated the majority of its revenue from collaboration arrangements rather than from product sales (it does not have broadly commercialized, marketed products). Key revenue streams...
Arvinas Holding Company Earnings Call Summary
The call was predominantly positive, with multiple clinical programs advancing, several data readouts planned through 2027, encouraging preclinical and biomarker findings, a cash runway extending into the second half of 2028, and significant year-over-year expense reductions. The main challenges were the ongoing U.S. clinical hold for ARV-102, limited durability and below-target dosing in the initial ARV-393 dataset, uncertainty around the clinical meaning of an ARV-102 endpoint, and the requirement for a partner to advance ARV-806.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Arvinas expects the first ARV-393 data disclosure in December, a second disclosure in mid-2027, ARV-027 healthy-volunteer data and SBMA patient dosing in the first half of 2027, ARV-6723 pembrolizumab dosing in the first half of 2027 and initial data in the second half of 2027, and ARV-102 phase I-B trial initiation in 2027 after next month’s E.U. and U.K. CTA submissions, with U.S. sites potentially added after the phase I-B trial. For ARV-393, management expects mid-teens or so T-cell patients in the first disclosure, views over really a 30% response rate as a reasonable bar at low doses, and noted current monotherapy BCL6 de grader response rates of over 50%; ARV-027 is targeting 50% reduction in polyQ-AR. The company had $558.9 million in cash equivalents, restricted cash, and marketable securities, compared with $685.4 million at the end of 2025, projected cash into the second half of 2028, and said current-quarter spending is expected to represent spending for the next few quarters; BCL6 is fully funded through next year and SBMA through the guidance period.
Arvinas Holding Company Financial Statement Overview
Summary
Improving reported results with sharp TTM revenue growth and a return to modest net income, supported by a very strong, low-leverage balance sheet. However, operating and free cash flow remain materially negative (ongoing cash burn), which keeps financial quality and sustainability below average.
Income Statement
58NeutralBalance Sheet
80PositiveCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 316.70M | 262.60M | 263.40M | 78.50M | 131.40M | 53.60M |
| Gross Profit | 305.40M | 257.40M | 263.40M | 78.50M | 131.40M | 53.60M |
| EBITDA | 3.90M | -75.30M | -191.70M | -359.70M | -253.40M | -184.90M |
| Net Income | 9.30M | -80.80M | -198.90M | -367.30M | -282.50M | -191.00M |
Balance Sheet | ||||||
| Total Assets | 675.10M | 717.90M | 1.09B | 1.30B | 1.27B | 1.58B |
| Cash, Cash Equivalents and Short-Term Investments | 567.90M | 685.40M | 1.04B | 1.26B | 1.21B | 1.50B |
| Total Debt | 8.20M | 8.90M | 9.70M | 3.20M | 5.50M | 5.00M |
| Total Liabilities | 112.90M | 284.10M | 529.70M | 644.60M | 703.90M | 799.90M |
| Stockholders Equity | 562.20M | 433.80M | 561.70M | 660.00M | 564.90M | 781.70M |
Cash Flow | ||||||
| Free Cash Flow | -208.80M | -275.70M | -261.10M | -350.70M | -280.30M | 554.70M |
| Operating Cash Flow | -207.00M | -273.80M | -259.30M | -347.80M | -273.50M | 559.40M |
| Investing Cash Flow | 277.90M | 407.60M | 34.70M | 203.50M | 242.80M | -1.31B |
| Financing Cash Flow | -91.50M | -91.40M | 7.90M | 374.70M | 4.70M | 278.60M |
Arvinas Holding Company Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Negative. The current price of 7.09 is below the 20-day moving average (MA) of 7.41, below the 50-day MA of 8.06, and below the 200-day MA of 9.66, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.90 is Neutral, neither overbought nor oversold. The STOCH value of 70.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARVN.
Arvinas Holding Company Risk Analysis
Arvinas Holding Company disclosed 71 risk factors in its most recent earnings report. Arvinas Holding Company reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksArvinas Holding Company Peers Comparison
Overall Rating
- ARVN54Neutral
PRLD53Neutral
MGNX46Neutral
ZNTL44Neutral
CCCC41Neutral
OLMA40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ARVN | 54Neutral | $491.70M | -47.27 | 1.91% | ― | -11.85% | 81.44% |
| PRLD | 53Neutral | $306.45M | -4.78 | -75.35% | ― | 220.34% | 55.73% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MGNX | 46Neutral | $148.42M | -10.59 | -31.27% | ― | 1.32% | 59.94% |
| ZNTL | 44Neutral | $175.14M | -0.72 | -87.95% | ― | -100.00% | 14.08% |
| CCCC | 41Neutral | $394.91M | -3.21 | -45.45% | ― | 2.33% | 36.86% |
| OLMA | 40Underperform | $618.61M | -3.47 | -48.22% | ― | ― | -10.16% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARVN | Arvinas Holding Company | 7.09 | -2.48 | -25.91% | |
| MGNX | MacroGenics Inc | 2.33 | 0.89 | 61.81% | |
| ZNTL | Zentalis Pharmaceuticals Inc | 1.78 | 0.44 | 32.84% | |
| PRLD | Prelude Therapeutics, Inc. | 3.78 | 2.39 | 171.94% | |
| CCCC | C4 Therapeutics, Inc. | 3.21 | 0.84 | 35.44% | |
| OLMA | Olema Pharmaceuticals, Inc. | 7.35 | -0.60 | -7.55% |
Arvinas Holding Company Corporate Events
Arvinas Reports Third-Quarter Results and Clinical Development Progress
NegativeOn November 3, 2026, Arvinas reported third-quarter results and a corporate update. During the quarter, it initiated patient dosing in the Phase 1/2 trial of ARV-6723, advanced enrollment of ARV-027 and ARV-393 studies, and presented ARV-102 data sho...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026